TK & Partners
VC Fund
Bangkok, Thailand
TK & Partners is a McKinsey venture capital firm.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries TK & Partners invests in
Stages TK & Partners invests in
Countries TK & Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $1.5M–$4.3M
Investment Focus
Industry
- Energy 1 (33%)
- Medical 1 (33%)
- Health Care 1 (33%)
- Biotechnology 1 (33%)
- Machine Learning 1 (33%)
Country
- Singapore 1 (33%)
- United States 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Tomas Koch
Founder and Chairman
|
Founder and Chairman | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Acurion
|
Acurion develops AI-driven diagnostic solutions that extract actionable genomic biomarker insights from standard pathology images to inform oncology treatment decisions. The company’s core product, OncoGaze™, analyzes digitized tumor biopsy slides to identify clinically relevant molecular features such as homologous recombination deficiency thatguide therapy selection more rapidly than conventional genomic testing. Acurion’s platform integrates into existing clinical workflows to support earlier precision medicine decisions for cancer care and is being expanded to detect additional biomarkers across various tumor types. The company collaborates with research and clinical partners to advance applications of its machine learning technology in oncology and related areas. | $4.3M / Seed / Apr 02, 2026 | |
|
Acurion
|
Acurion develops AI-driven diagnostic solutions that extract actionable genomic biomarker insights from standard pathology images to inform oncology treatment decisions. The company’s core product, OncoGaze™, analyzes digitized tumor biopsy slides to identify clinically relevant molecular features such as homologous recombination deficiency thatguide therapy selection more rapidly than conventional genomic testing. Acurion’s platform integrates into existing clinical workflows to support earlier precision medicine decisions for cancer care and is being expanded to detect additional biomarkers across various tumor types. The company collaborates with research and clinical partners to advance applications of its machine learning technology in oncology and related areas. | $2.1M / Seed / Jan 02, 2026 | |
HYDGEN
|
HydGen offers clean hydrogen solutions for an environmentally conscious future. | $1.5M / Seed / Feb 13, 2025 |
Co-Investors
Asian Fund For Cancer Research
1 deal together
Bootstrap Venture Partners
1 deal together
Cloudberry Pioneer Investments
1 deal together
Mesa Verde Venture Partners
1 deal together
National Foundation for Cancer Research
1 deal together
National University of Singapore
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does TK & Partners invest in?
TK & Partners invests primarily in Energy, Medical and Health Care startups, most often at Seed stage. Most of the 3 investments tracked by Shizune back companies in Singapore. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is TK & Partners's check size?
TK & Partners typically joins rounds of $1.5M–$4.3M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds TK & Partners participates in.
How do I contact TK & Partners?
Public channels for TK & Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at TK & Partners?
The team at TK & Partners includes Tomas Koch (Founder and Chairman). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
